Market Cap
₹11,457 Cr.
P/E
148.60
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

9 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
-1.13%
3yr Average
8.09%
5yr Average
10.45%
Net Profit Margin
Latest
-0.97%
3yr Average
6.5%
5yr Average
8.16%
ROCE
Latest
2.85%
3yr Average
8.73%
5yr Average
10.85%
Debt to Equity
Latest
0.63
3yr Average
0.58
5yr Average
0.71
Market Share
62% (as of Mar 18)
Acetic Anhydride - Domestic Market Share
0.06% (as of Jul 22)
Anti - Diabetes - Market Share
0.06% (as of Jul 22)
Cardiovascular - Market Share
0.01% (as of Feb 21)
Neurological - Market Share
0.02% (as of Jul 22)
Pharmaceutical Sector - Market Share
0.03% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
18% (as of Mar 18)
Vitamin B3 - Global Market Share
64% (as of Mar 18)
Vitamin B4 - Domestic Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Segment Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Contract Research

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Pharmaceuticals

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Capex

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • Australia DMF fillings (.)
    • US DMF Filings (.)
    • Canada DMF fillings (.)
    • Japan DMF Filings (.)
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • Number of ANDA's Filed in Europe
    • Number of ANDA's Approved in Europe
    • Number of ANDA's Filed in Canada
    • Number of ANDA's Approved by Canada
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis